14 March 2019 - Adults in the UK with PD-L1 positive, unresectable locally advanced or metastatic triple-negative breast cancer have won early access to Roche’s immunotherapy Tecentriq in combination with nab-paclitaxel chemotherapy.

The move follows a decision by the UK’s Medicines and Healthcare products Regulatory Agency to include the drug in the country’s Early Access to Medicines Scheme (EAMS) , which provides patients access to innovative medicines before they are officially approved by the European Medicines Agency.

Roche will fund access to the treatment as per the terms of the EAMS agreement, under which triple negative breast cancer patients whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease will be eligible for the scheme.

Read Pharma Times article